Royalty Pharma (RPRX) Change in Acquisitions & Divestments (2019 - 2026)

Royalty Pharma has reported Change in Acquisitions & Divestments for 8 years, with the latest figure at $4.3 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 65.68% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.0 million (down 58.1% YoY) and the FY2025 annual result came in at $21.2 million, up 7.28% from the prior year.
• Change in Acquisitions & Divestments advanced to $4.3 million in Q1 2026 per RPRX's latest filing, from $2.9 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $274.6 million in Q1 2022 and troughed at -$24.4 million in Q3 2023.
• A 5-year average of $53.9 million and a median of $8.5 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2022 and 2023: Change in Acquisitions & Divestments jumped 1657.49% in 2022, then plunged 116.17% in 2023.
• Over 5 years, Change in Acquisitions & Divestments stood at $115.6 million in 2022, then plunged by 78.91% to $24.4 million in 2023, then slumped by 48.4% to $12.6 million in 2024, then tumbled by 77.12% to $2.9 million in 2025, then jumped by 50.0% to $4.3 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $4.3 million, $2.9 million, and $2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.